Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of nonsmall-cell lung cancer (NSCLC). It carries a poor prognosis, even among other subtypes of NSCLC. Currently, most treatment strategies for PSC are derived from regimens aimed at managing soft tissue sarcomas or NSCLC. The use of doxorubici...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jan Alberto Paredes Mogica, Eduardo Reyes Sanchez, Daniela Arantza Zaragoza Morales, Nathalie Pierre-Louis Guillen, Manuel Ernesto Magallanes Maciel
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	neoplasms lung neoplasms carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a77b6366e9844f7d91dcc5642bebfd03
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a77b6366e9844f7d91dcc5642bebfd03
record_format	dspace
spelling	oai:doaj.org-article:a77b6366e9844f7d91dcc5642bebfd032021-12-02T12:40:23ZRapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed1662-657510.1159/000520190https://doaj.org/article/a77b6366e9844f7d91dcc5642bebfd032021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/520190https://doaj.org/toc/1662-6575Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of nonsmall-cell lung cancer (NSCLC). It carries a poor prognosis, even among other subtypes of NSCLC. Currently, most treatment strategies for PSC are derived from regimens aimed at managing soft tissue sarcomas or NSCLC. The use of doxorubicin plus ifosfamide and pemetrexed has been well established in the management of soft tissue carcinoma and other nonsmall-cell lung cancers, respectively. We report the case of a 69-year-old male diagnosed with PSC who was managed with doxorubicin plus ifosfamide and pemetrexed therapy. Our patient initially responded to the therapy but had rapid progression and died 8 months after the initiation of treatment. Upon genetic analysis, it was revealed the patient had overexpression of the MDM2 protein, which has been associated with poor response to therapy. This case highlights the need for a personalized treatment approach, as well as the need for a standardized treatment regimen for managing PSC.Jan Alberto Paredes MogicaEduardo Reyes SanchezDaniela Arantza Zaragoza MoralesNathalie Pierre-Louis GuillenManuel Ernesto Magallanes MacielKarger Publishersarticleneoplasmslung neoplasmscarcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1677-1681 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	neoplasms lung neoplasms carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	neoplasms lung neoplasms carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jan Alberto Paredes Mogica Eduardo Reyes Sanchez Daniela Arantza Zaragoza Morales Nathalie Pierre-Louis Guillen Manuel Ernesto Magallanes Maciel Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed
description	Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of nonsmall-cell lung cancer (NSCLC). It carries a poor prognosis, even among other subtypes of NSCLC. Currently, most treatment strategies for PSC are derived from regimens aimed at managing soft tissue sarcomas or NSCLC. The use of doxorubicin plus ifosfamide and pemetrexed has been well established in the management of soft tissue carcinoma and other nonsmall-cell lung cancers, respectively. We report the case of a 69-year-old male diagnosed with PSC who was managed with doxorubicin plus ifosfamide and pemetrexed therapy. Our patient initially responded to the therapy but had rapid progression and died 8 months after the initiation of treatment. Upon genetic analysis, it was revealed the patient had overexpression of the MDM2 protein, which has been associated with poor response to therapy. This case highlights the need for a personalized treatment approach, as well as the need for a standardized treatment regimen for managing PSC.
format	article
author	Jan Alberto Paredes Mogica Eduardo Reyes Sanchez Daniela Arantza Zaragoza Morales Nathalie Pierre-Louis Guillen Manuel Ernesto Magallanes Maciel
author_facet	Jan Alberto Paredes Mogica Eduardo Reyes Sanchez Daniela Arantza Zaragoza Morales Nathalie Pierre-Louis Guillen Manuel Ernesto Magallanes Maciel
author_sort	Jan Alberto Paredes Mogica
title	Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed
title_short	Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed
title_full	Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed
title_fullStr	Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed
title_full_unstemmed	Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed
title_sort	rapidly progressive lung sarcomatoid carcinoma managed with doxorubicin plus ifosfamide and pemetrexed
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/a77b6366e9844f7d91dcc5642bebfd03
work_keys_str_mv	AT janalbertoparedesmogica rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed AT eduardoreyessanchez rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed AT danielaarantzazaragozamorales rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed AT nathaliepierrelouisguillen rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed AT manuelernestomagallanesmaciel rapidlyprogressivelungsarcomatoidcarcinomamanagedwithdoxorubicinplusifosfamideandpemetrexed
_version_	1718393758038360064

Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed

Ejemplares similares